Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Profit After Tax (2016 - 2025)

Integra Lifesciences Holdings' Profit After Tax history spans 17 years, with the latest figure at -$1.7 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 108.77% year-over-year to -$1.7 million; the TTM value through Dec 2025 reached -$516.5 million, down 7338.77%, while the annual FY2025 figure was -$516.5 million, 7337.7% down from the prior year.
  • Profit After Tax for Q4 2025 was -$1.7 million at Integra Lifesciences Holdings, up from -$5.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $52.9 million in Q4 2022 and bottomed at -$484.1 million in Q2 2025.
  • The 5-year median for Profit After Tax is $19.7 million (2023), against an average of -$5.3 million.
  • The largest annual shift saw Profit After Tax skyrocketed 9603.52% in 2021 before it plummeted 3803.18% in 2025.
  • A 5-year view of Profit After Tax shows it stood at $45.4 million in 2021, then rose by 16.66% to $52.9 million in 2022, then crashed by 62.54% to $19.8 million in 2023, then fell by 2.01% to $19.4 million in 2024, then plummeted by 108.77% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Profit After Tax are -$1.7 million (Q4 2025), -$5.4 million (Q3 2025), and -$484.1 million (Q2 2025).